Mesenchymal Stromal Cells for Treatment of the Acute Respiratory Distress Syndrome: The Beginning of the Story
Overview
Authors
Affiliations
In spite of decades of research, the acute respiratory distress syndrome (ARDS) continues to have an unacceptably high mortality and morbidity. Mesenchymal stromal cells (MSCs) present a promising candidate for the treatment of this condition and have demonstrated benefit in preclinical models. MSCs, which are a topic of growing interest in many inflammatory disorders, have already progressed to early phase clinical trials in ARDS. While a number of their mechanisms of effect have been elucidated, a better understanding of the complex actions of these cells may pave the way for MSC modifications, which might enable more effective translation into clinical practice.
Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome.
Ngai H, Kim D, Hammad M, Gutova M, Aboody K, Cox C J Cell Mol Med. 2022; 26(9):2483-2504.
PMID: 35426198 PMC: 9077311. DOI: 10.1111/jcmm.17265.
Fergie N, Todd N, McClements L, McAuley D, OKane C, Krasnodembskaya A FASEB J. 2019; 33(4):5585-5598.
PMID: 30649987 PMC: 6436662. DOI: 10.1096/fj.201802056R.